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Severe sepsis remains a poorly understood systemic
inflammatory condition with high mortality rates
and limited therapeutic options in addition to organ
support measures. Here we show that the clinically
approved group of anthracyclines acts therapeuti-
cally at a low dose regimen to confer robust protec-
tion against severe sepsis inmice. This salutary effect
is strictly dependent on theactivationofDNAdamage
response and autophagy pathways in the lung, as
demonstrated by deletion of the ataxia telangiectasia
mutated (Atm) or the autophagy-related protein 7
(Atg7) specifically in this organ. The protective effect
of anthracyclines occurs irrespectively of pathogen
burden, conferring disease tolerance to severe
sepsis. These findings demonstrate that DNA dam-
age responses, including the ATM and Fancony Ane-
mia pathways, are important modulators of immune
responses and might be exploited to confer protec-
tion to inflammation-driven conditions, including
severe sepsis.
INTRODUCTION
Sepsis is a life-threatening condition that arises as a systemic
inflammatory response to an infection (Bone et al., 1992; Levy874 Immunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc.et al., 2003). It includes a continuum of clinical severity ranging
from systemic inflammatory response syndrome (SIRS), sepsis,
severe sepsis, to septic shock (Suffredini and Munford, 2011). It
is the leading cause of death in intensive care units and the
third cause of overall hospital mortality (Angus and Wax, 2001;
Ulloa and Tracey, 2005). In spite of substantial improvement in
diagnosis and support measures, the global annual mortality
rate is 28% (Hotchkiss and Karl, 2003), ranging from less
than 10% in SIRS to up to 70% in septic shock (Angus and
Wax, 2001; Annane et al., 2003). The pathophysiology of sepsis
remains poorly understood. As a result, the basic elements of
treatment—early antibiotics, prompt control of the source of
infection, and organ support—have not changed substantially
in the last 50 years, and attempts to translate basic research re-
sults into effective new interventions have been met with limited
or no success (Suffredini and Munford, 2011). In the same
period, the incidence of sepsis and its economic burden has
increased by 1%each year (Martin et al., 2003; Ulloa and Tracey,
2005), indicating the urgent need for novel therapeutic options.
Inflammation is a response to harmful stimuli that limits tissue
damage and aims at restoring homeostasis (Medzhitov, 2008).
Pathogen-associated molecular patterns (PAMPs) on microor-
ganisms and damage-associated molecular patterns (DAMPs)
originating fromdying cells are sensed by the host through germ-
line-encoded pattern-recognition receptors (PRRs) that recog-
nize conserved signature structures in nonself and self (Janeway
andMedzhitov, 2002). These sensors are present in both profes-
sional (including neutrophils, macrophages, and dendritic cells)
and nonprofessional immune cells and their activation initiates
intracellular signaling cascades leading to the transcriptional
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chemokines. Inflammation needs to be effectively terminated
after removal of the original trigger for repair of damaged tissue
to occur. In the susceptible host, overproduction of inflammatory
mediators or an exaggerated response to their presence can
lead to septic shock, tissue destruction, or permanent loss of
function (Takeuchi and Akira, 2010).
There are two evolutionarily conserved defense strategies
against infection that can limit host disease severity. One relies
on reducing pathogen load, i.e., resistance to infection, whereas
the other provides host tissue damage control, limiting dis-
ease severity irrespectively of pathogen load, i.e., tolerance to
infection (Ra˚berg et al., 2009; Schneider and Ayres, 2008). As
demonstrated originally for plants and thereafter in Drosophila,
tolerance to infection also operates in mammals, as revealed
for Plasmodium (Ra˚berg et al., 2007; Seixas et al., 2009) and
polymicrobial infections in severe sepsis (Larsen et al., 2010).
Here we show in an experimental mouse model that anthracy-
clines confer strong protection against sepsis by increasing
disease tolerance to infection; that is, acting irrespectively of
pathogen burden. We further show that ATM (ataxia telangiecta-
sia mutated) kinase and the induction of autophagy are strictly
required for the in vivo protection against sepsis. These molec-
ular pathways provide strong damage control in tissues, specif-
ically in the lung.
RESULTS
AnthracyclinesConfer StrongProtection against Severe
Sepsis
In an in vitro chemical screen using 2,320 compounds, we
identified several lead candidates capable of inhibiting inflam-
matory cytokine production in response to E. coli challenge by
the THP-1 macrophage line (see Figure S1A and Table S1 avail-
able online). This inhibitory effect was dissociated from cytotox-
icity of the compounds tested on THP-1 cells (Figure S1B).
Among these, we found three representatives of the anthracy-
cline family of chemotherapeutic agents namely epirubicin,
doxorubicin, and daunorubicin, and validated their inhibitory
activity on cytokine production (Figure S1C).
We then used the cecal ligation and puncture (CLP) mouse
model of experimental sepsis to investigate the in vivo effects
of epirubicin (Rittirsch et al., 2009). In CLP, sepsis results from
a polymicrobial infection of abdominal origin, leading to bacter-
emia and a systemic inflammatory response (Rittirsch et al.,
2009). We adjusted CLP severity to a high-grade sepsis, where
at least 80% of C57BL/6 mice succumbed within 48 hr after the
initial procedure. Under these conditions, epirubicin adminis-
tered intraperitoneally (i.p.) at the timeofCLPandagain 24hr later
in a total of 1.2 mg/g of bodyweight reproducibly and significantly
(p < 0.001) increased the survival of C57BL/6 mice subjected
to CLP by nearly 80%, without the use of antibiotics (Figure 1A).
A similar protective effect was observed in epirubicin-treated
animals with the same dose and schedule but administered i.v.
(Figure S1D). This appeared to be a general property of the
anthracycline family because other representative members of
this family of drugs identified in the initial chemical screen
conferred a similar degree of protection against CLP (Figure 1B).
The protective effect of anthracyclines was not dependent onIthe mouse strain as outbread NMRI mice were similarly pro-
tected by epirubicin (Figure 1C). Epirubicin was equally effective
against another clinically relevant pathogen causing sepsis,
K. pneumoniae administered intranasally (Figure 1D), arguing
that epirubicin can be effective in the treatment of sepsis of
different origins in addition to peritoneal sepsis. Mice previously
subjected to CLP and treated with epirubicin were not immuno-
compromised because they could clear a secondary intranasal
viral infection similarly to controlmice (Figure 1E). Taken together,
these results indicate that low doses of the anthracycline family
of chemotherapeutic agents confer strong protection against
severe sepsis, without causing host immunosuppression.
Epirubicin Acts Therapeutically to Promote Disease
Tolerance to Severe Sepsis
We found that in epirubicin-treated mice subjected to CLP, the
bacterial load in blood and target organs of sepsis, e.g., lung,
liver, kidney, and spleen 24 hr post-CLP did not differ from that
of untreated controls (Figure 2A). Although at 48 hr post-CLP,
we noticed a trend toward a lower bacterial load in the target
organs of epirubicin-treated animals, the differences were not
statistically significant, even if most untreated control animals
die between 24 and 48 hr after the CLP procedure. These results
raised the possibility that the protective effect of epirubicin in vivo
is related to disease tolerance without directly affecting the path-
ogen burden (Medzhitov et al., 2012). This idea was supported
by the observation that the serum concentrations of several
markers of tissue damage such as LDH (lung and general cellular
damage), CK (muscle), ALT (liver), and urea (kidney) were sub-
stantially reduced to almost basal levels in epirubicin-treated
mice, 24 hr after CLP, compared to untreated mice (Figure 2B).
In addition, we observed a substantial reduction in the levels of
inflammatory mediators including tumor necrosis factor (TNF),
interleukin-1b (IL-1b), IL-6, and HMGB1 compared to nontreated
CLP mice (Figure 2C). We have also observed improvement of
histological lesions in the lung, liver, and kidney after CLP by
treatment with epirubicin (Figure S2). To explore this further in
the absence of bacteria, we found that the drug protected
C57BL/6 mice from lethal septic shock caused by lipopolysac-
charide (LPS, endotoxin) (Figure 2D).
Large spectrum antibiotics such as meropenem are very
effective at lowering bacteremia and are standard drugs used
in sepsis (Russell, 2006). We tested the efficacy of meropenem
in CLP in comparison to epirubicin and found that although mer-
openem delayed the death rate of CLP-subjectedmice, it did not
prevent mortality (Figure 2E), in spite of a strong impact on bac-
terial burden (Figure 2F). This was in sharp contrast to the action
of epirubicin, which did not interfere with bacteremia (Figure 2F)
but prevented CLP-induced mortality (Figure 2E), again arguing
for a role of epirubicin in conferring disease tolerance against
severe sepsis (Larsen et al., 2010; Medzhitov et al., 2012).
Both epirubicin andmeropenem decreased the amounts of IL-
1b, TNF, andHMGB1 in the serum ofmice subjected to CLP (Fig-
ure 2G). This indicates that whereas decreased circulating levels
of inflammatory mediators might contribute to confer protection
against severe sepsis, inhibition of IL-1b, TNF, andHMGB1 is not
sufficient per se to explain the protective effect of epirubicin,
which is in accordance with what is observed for other therapeu-
tic approaches in the clinical setting (Hotchkiss and Karl, 2003).mmunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc. 875
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Figure 1. Epirubicin Affords Protection against Severe Sepsis
(A) Survival of C57BL/6 WT animals subjected to CLP treated with carrier (PBS) or epirubicin (Epi) (0.6 mg/g body weight) at the time of procedure and 24 hr later.
(B) Survival of C57BL/6 WT animals subjected to CLP treated with carrier (PBS), epirubicin (Epi), doxorubicin (Doxo), or daunorubicin (Dauno). Treatment
schedule and doses as in (A).
(C) Survival of NMRI mice subjected to CLP and treated with carrier (PBS) or epirubicin (Epi) as in (A).
(D) Survival of C57BL/6 WT animals following intranasal inoculation of Klebsiella pneumoniae and treated with carrier (PBS) or epirubicin (Epi) as in (A).
(E) Quantification of infectious viral MuHV-4 particles in lung of C57BL/6 WT animals previously subjected to mock CLP (S), mock CLP treated with epirubicin
(S+E) or CLP treatedwith epirubicin (C+E). Epirubicin treatment dose and schedule as in (A).Mice were intranasally inoculated with 1,000 PFU ofMuHV-4 on day 3
post-CLP and viral particles quantified by plaque assay at days 6 and 12 after viral infection. Each circle represents individual animals and horizontal lines indicate
arithmetic means ± SEM from two independent assays. The dashed horizontal line represents the limit of detection of the assay. n.s., not significant; *p < 0.05;
**p < 0.01; ***p < 0.001 (log-rank [Mantel-Cox] test for A to D and Mann-Whitney test for E). See also Figure S1 and Table S1.
Immunity
Anthracyclines Induce Tolerance to SepsisTaken together, these data suggest that epirubicin acts through
an additional alternative mechanism to cytokine inhibition to
confer tolerance to sepsis.
Epirubicin Protection against Sepsis Is Mediated by
ATM
Next, in order to explore the molecular mechanism behind the
protective effects of anthracyclines, we used our in vitro assay
system to perform a short hairpin RNA (shRNA)-based screen
in THP-1 cells, focusing on kinases and phosphatases and
with IL-1b and TNF secretion as assay readouts.While our in vivo
results suggested the possibility that anthracyclines ameliorate
the lethal effects of sepsis by a mechanism affecting tissue toler-
ance, we reasoned that our in vitro assay would be useful for the
identification of candidate pathwaysmediating the anthracycline
effects.We found several negative regulators of IL-1b production
in response to E. coli challenge, including the genes encoding
ATM, checkpoint kinase 1 (CHEK1) and ataxia telangiectasia
and Rad3 related (ATR) (Figure S3; Table S2). These findings
suggest that DNA damage response (DDR) components are
negative regulators of IL-1b secretion. By using a phospho-
specific antibody against the activated form of ATM, we found
that although E. coli alone was a poor but reproducible ATM
activator (Figure S3), epirubicin alone or in combination with
E. coli triggered a robust ATM activation (Figure S3). This was
confirmed with immunoblotting (Figure S3).876 Immunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc.ATM is amaster regulator of theDDR (Ciccia andElledge, 2010)
and is known to be activated by anthracyclines and other DNA-
damaging agents (Siu et al., 2004). Therefore, we used ATM-defi-
cient mice to test the contribution of the DDR to the protective
effect of anthracyclines against severe sepsis. ATM-deficient
(Atm/) mice were not protected by epirubicin against CLP and
died with similar kinetics to those of wild-type (WT, Atm+/+) ani-
mals that were treated with PBS alone (Figure 3A). We conclude
that ATM expression is necessary to mediate the protective
effect of epirubicin in sepsis. In striking contrast to WTmice (Fig-
ures 2B and 2C), in the absence of ATM, epirubicin no longer
normalized the serologic markers of organ lesion (Figure 3B) or
decreased the levels of inflammatorymediators (Figure 3C).How-
ever, in mice subjected to CLP and treated with etoposide (after
in vivo titration to find the best andmost effective dose), an agent
known to cause DNA double-strand breaks and to activate ATM-
dependentpathways (MontecuccoandBiamonti, 2007),mortality
inducedbyCLPwasonlypartially rescued (Figure3D), suggesting
that ATM is necessary but not sufficient for the protection
conferred by anthracyclines against sepsis.
In addition to double-strand breaks (repaired in an ATM-
dependent manner), anthracyclines also cause DNA interstrand
crosslinks, a DNA lesion known to be repaired by the Fanconi
Anemia (FA) pathway (Ciccia and Elledge, 2010). Interestingly,
FA patients were reported to spontaneously overproduce TNF
(Briot et al., 2008; Vanderwerf et al., 2009), possibly because
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Figure 2. Epirubicin Promotes Disease Tolerance to Severe Sepsis
(A) Polymicrobial load (CFUs) in blood, lung, liver, kidney, and spleen, at indicated time points, of C57BL/6 animals undergoing CLP and treatedwith PBS (C+P) or
epirubicin (C+E) (0.6 mg/g body weight) at the time of procedure and 24 hr later. Each circle represents individual animals. Horizontal lines indicate arithmetic
means ± SEM.
(B) and (C) Epirubicin counteracts tissue damage and inflammation associated with CLP as assessed by (B) LDH, CK, ALT, urea, and (C) TNF, IL-1b, IL-6, and
HMGB1 plasma concentrations in C57BL/6 WT animals 24 hr after mock CLP (S) (n = 2) or CLP followed by treatment with PBS (C+P) (n = 5) or epirubicin (C+E)
(n = 7) as in (A). Results shown represent arithmetic means ± SEM from duplicate (B) or triplicate (C) readings per animal.
(D) Survival of C57BL/6 WT animals following lethal LPS injection and treatment with carrier (PBS) or epirubicin (Epi) as in (A).
(E) Survival of C57BL/6 WT animals subjected to CLP treated with carrier (PBS), meropenem (40 mg/g body weight/day), or epirubicin (Epi) as in (A).
(F) CFUs in blood, at indicated time, of C57BL/6 animals undergoingmock CLP (S) or CLP followed by treatment with PBS (C+P), epirubicin (C+E), or meropenem
(C+M) as in (A). Each circle represents individual animals. Horizontal lines indicate arithmetic means ± SEM.
(G) IL-1b, TNF, and HMGB1 plasma concentrations in C57BL/6 WT animals 24 hr after CLP followed by treatment with PBS (C+P) (n = 4), epirubicin (C+E) (n = 5),
or meropenem (C+M) (n = 5) as in (C). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (log-rank [Mantel-Cox] test for D and E,Mann-Whitney test for A and F,
and unpaired t test for B, C and G). See also Figure S2.
Immunity
Anthracyclines Induce Tolerance to Sepsisthe FA protein FANCD2 can directly inhibit TNF promoter activ-
ity (Matsushita et al., 2011). In THP-1 cells, we observed that
FANCD2 is activated in an ATM-independent manner upon epi-
rubicin treatment, as shown by its monoubiquitination (Fig-
ure 3E). These findings support the independence of signaling
events initiated by the generation of DNA double-strand breaks
and DNA interstrand crosslinks. We examined the contribution
of this pathway for epirubicin protection of CLP and found that
Fancd2/mice were slightly but significantly (p < 0.05) impaired
for the protective effects (Figure 3F).IThese results suggest that activation of DDR is protective
against sepsis. To further test this hypothesis, we have used
whole-body sublethal g irradiation. We found a significant
increase in the number of cells with gH2AX-positive foci (p <
0.001), a surrogate marker of ATM activation (Ciccia and
Elledge, 2010), in the lungs of whole-body sublethal g-irradi-
ated mice as compared to controls (Figure 3G). Mice subjected
to CLP that were irradiated showed a significant increased
survival (p < 0.001) as compared to nonirradiated mice (Fig-
ure 3H). We conclude that the protective phenotype inducedmmunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc. 877
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Figure 3. The Protection Afforded by Epirubicin against Severe Sepsis Is Mediated by ATM
(A) Survival of Atm+/+ and Atm / C57BL/6 animals subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in Figure 1.
(B) LDH, CK, ALT, urea, and (C) TNF, IL-1b, and IL-6 plasma concentrations in Atm / C57BL/6 animals 24 hr after mock CLP (S) (n = 2) or CLP followed by
treatment with PBS (C+P) (n = 8) or epirubicin (C+E) (n = 8) as in (A). Results shown represent arithmetic means ± SEM from triplicate readings per animal.
(D) Survival of PBS-, etoposide (Eto)-, and epirubicin (Epi)-treated WT C57BL/6 animals undergoing CLP. Etoposide dose was 2 mg/g body weight. Treatment
schedule is as in (A).
(E) FANCD2 and Ub-FANCD2 protein levels by immunoblotting in THP-1 cells following E. coli challenge after a preincubation (1 hr) with carrier, epirubicin, or
KU-55933 as indicated.
(F) Survival of Fancd2+/+ and Fancd2/ animals subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in (A).
(G) Representative sections of gH2AX staining and percentage of gH2AX+ cells per field (right panel) in lungs isolated 1 hr after mice were subjected to whole-
body g irradiation (4 Gy). Results shown represent arithmetic means ± SD from three fields.
(H) Survival of C57BL/6 WT animals subjected to CLP following whole-body g irradiation (4Gy) or treated with carrier (PBS) or epirubicin (Epi) as in (A).
n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (log-rank [Mantel-Cox] test for A, D, F and H and unpaired t test for B, C, and G). See also Figure S3
and Table S2.
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Anthracyclines Induce Tolerance to Sepsisby epirubicin is dependent on the activation of multiple path-
ways downstream of a DDR. The activation of the ATM
pathway is the main contributor, but the full protection requires
the activation of additional DDR pathways, including the FA
pathway.878 Immunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc.The Protective Effect of Epirubicin Is Dependent on the
Autophagy Pathway
Although it is possible that the dominant ATM-mediated protec-
tion against sepsis might rely on ROS scavenging (Cosentino
et al., 2011), on the induction of apoptosis of inflammatory cells
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Figure 4. The ATM-Dependent Protection of Epirubicin against Severe Sepsis Relies on the Induction of Autophagy
(A) Survival of Lc3b+/+ and Lc3b/ animals subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in Figure 1.
(B) LDH, CK, ALT, urea, and (C) TNF, IL-1b, and IL-6 plasma concentrations in Lc3b/ animals 24 hr after mock CLP (S) (n = 2) or CLP followed by treatment with
PBS (C+P) (n = 4) or epirubicin (C+E) (n = 7) as in (2B). Results shown represent arithmetic means ± SEM from triplicate readings per animal. n.s., not significant;
*p < 0.05; **p < 0.01; ***p < 0.001 (log-rank [Mantel-Cox] test for A, unpaired t test for B and C). See also Figure S4.
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Anthracyclines Induce Tolerance to Sepsis(Garrison et al., 2010), on the preservation of genomic stability
(Westbrook and Schiestl, 2010), or on the biogenesis of anti-in-
flammatory microRNAs such as miR-146a (Zhang et al., 2011),
we found no significant contribution for any of these processes
(Figure S4). We therefore explored a possible role for autophagy
in this process, given that ATM is a negative regulator of mTOR,
which is an inhibitor of autophagy (Alexander et al., 2010a;
Alexander et al., 2010b). By using autophagy-defective (Lc3b/)
mice, we found that the autophagy pathway is required for
the in vivo effect of epirubicin (Figure 4A). Similarly to Atm/
mice (Figures 3B and 3C), epirubicin was not able to decrease
the serologic markers associated with organ lesion (Figure 4B)
or to normalize cytokine levels in autophagy-defective mice
(Figure 4C).
We then used LC3b-GFP mice to study the contribution of
the autophagy pathway in the protection conferred by epirubi-
cin. While FACS analysis shows that CLP alone induces LC3b
aggregation in different splenocyte populations, namely mono-
cytes and neutrophils, epirubicin treatment did not increase
the autophagy pathway in these critical players in sepsis (Fig-
ure 5A). We then tested the impact of epirubicin on the survival
of a conditional depletion of Atg7 specifically in neutrophils and
monocytes upon CLP, with Atg7loxP/loxP LysMCre GFP-LC3b
animals. Strikingly, these animals were equally protected by
epirubicin as compared to control mice (Figure 5B), suggesting
that the autophagy pathway is not required in the myeloid
compartment for the protective effects of epirubicin against
sepsis.
Autophagy can be effectively monitored by the conversion and
immobilization of LC3 (Kabeya et al., 2000). Because the auto-
phagy pathway was not required in the myeloid compartment
for protection against sepsis by epirubicin, we then looked at
target organs of sepsis (lung, liver, and kidney) by using immuno-
bloting to identify lipidation of LC3b as indicative of activation ofIthe autophagy pathway. We found that epirubicin specifically
induced lipidation of LC3b in the lung at 6 hr, but not in the liver
or kidney (Figure 5C). Although LC3 was transiently lipidated
after CLP in the liver at 6 and 24 hr as previously reported (Chien
et al., 2011), levels of LC3 were not altered by epirubicin treat-
ment (Figure 5C). We have further confirmed that autophagy
was induced in the lung as shown by the increase of LC3b
positive vesicles in lung sections at 6 hr and 24 hr comparing
epirubicin treated and nontreated mice (Figure 5D).
We then deleted Atg7 specifically in the lung (Figure S5) by
using an adenovirus-expressing CRE (Adcre) to intranasally
infect Atg7loxP/loxP mice (Komatsu et al., 2005). When subjected
to CLP, these mice were no longer protected from CLP by
epirubicin treatment (Figure 5E). In contrast to control mice, in
Atg7loxP/loxP Adcre mice, the treatment with epirubicin does not
improve the levels of circulating markers of organ lesion (Fig-
ure 5F). Accordingly, we observed a significant protective effect
in survival after overexpression of ATG7 in the lung with adeno-
virus (Figure 5G).
By assessing the levels of gH2AX in the lungs of control or
epirubicin-treated CLP-subjected mice, we found a significant
increase in the number of cells with gH2AX-positive foci in lungs
of epirubicin-treated mice (Figure 5H). To test whether ATM acti-
vation was also required in the lung, we used AtmloxP/loxP
mice and Adcre to delete ATM specifically in the lung. Upon
Adcre-mediated ATM deletion in the lung, mice were no longer
protected against sepsis by treatment with epirubicin (Figure 5I).
We therefore conclude that the protective effect of epirubicin in
sepsis is, at least in part, dependent on the activation of ATM and
of autophagy in target organs, namely the lung. These conclu-
sions are further supported by intranasal delivery of epirubicin
or etoposide to the lung (Figure 5J) because the protective
effects as measured by survival are similar to the i.p. administra-
tion of those drugs (Figure 5J).mmunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc. 879
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Figure 5. The Protective Effect of Epirubicin Is Dependent on the Activation of ATM and the Autophagy Pathway in the Lung
(A) GFP expression in blood monocytes and neutrophils, isolated from transgenic LC3b-GFP animals, 24 hr after mice were subjected to mock CLP (S) or CLP
followed by treatment with PBS (C+P) or epirubicin (C+E) (0.6 mg/g body weight) at the time of procedure and 24 hr later. Each circle represents individual animals.
Horizontal lines indicate arithmetic means ± SEM.
(B) Survival of Atg7loxP/loxP and Atg7loxP/loxP LysMcre/cre mice subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in (A).
(C) LC3B-I and LC3B-II protein levels by immunoblotting using a specific antibody against LC3B in lung, liver and kidney, isolated at the indicated times, of naive
C57BL/6 animals (C) or mice subjected to mock CLP (S) or CLP followed by treatment with PBS (C+P) or epirubicin (C+E) as in (A).
(D) Representative sections of LC3b staining in lungs, isolated at the indicated times, of mice subjected to CLP followed by treatment with PBS (C+P) or epirubicin
(C+E) as in (A).
(E) Survival of WT (B6) and Atg7loxP/loxP animals subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in (B) 5 days after
inhalation of adenoviral vector encoding Cre (AdCre).
(F) LDH, CK, ALT, and urea plasma concentrations inWT (B6 AdCre) andAtg7loxP/loxP AdCre animals 24 hr after mock CLP (S) (n = 2 for B6 AdCre) or CLP followed by
treatment with PBS (C+P) (n = 5 for B6 AdCre and n = 2 for Atg7loxP/loxP AdCre) or epirubicin (C+E) (n = 6 for B6 AdCre and n = 3 for Atg7loxP/loxP AdCre) as in (A).
(G) Survival of WT (B6) animals subjected to CLP 4 days after inhalation of adenoviral vector encoding GFP (AdGFP) or Atg7 (AdATG7).
(H) Representative sections of gH2AX staining and percentage of gH2AX+ cells per field (right panel) in lungs, isolated 6 hr after mice were subjected to CLP
followed by treatment with PBS (C+P) or epirubicin (C+E) as in (A). Results shown represent arithmetic means ± SD from ten fields.
(I) Survival of WT (B6) and AtmloxP/loxP animals subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in (B) 5 days after
inhalation of AdCre.
(J) Survival of C57BL/6 WT animals subjected to CLP treated with carrier (PBS), etoposide (2 mg/g body weight) or epirubicin (Epi) (0.6 mg/g body weight)
intranasally, at the time of procedure and 24 hr later. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (log-rank [Mantel-Cox] test for B, E, G, I and J, Mann-
Whitney test for A, and unpaired t test for F and H, right panel). See also Figure S5.
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Anthracyclines Induce Tolerance to SepsisEpirubicin Has a 24 hr Therapeutic Window to Protect
against Sepsis
Finally, we studied the therapeutic window of epirubicin in mice.
When given alone, epirubicin conferred strong protection at the
time of the procedure or until 3 hr after the initiation of CLP (Fig-
ure 6A). When administered only 6 hr after CLP, epirubicin
quickly lost its protective effect (Figure 6A). However, if given
in combination with meropenem, even when this antibiotic is
only administered 12 hr after CLP, low-dose epirubicin conferred
complete protection until at least 24 hr after the initial procedure
(Figures 6B and 6C). These results suggest that anthracyclines880 Immunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc.can be used not only to prevent sepsis but also that they can
act therapeutically when their administration is combined with
a large-spectrum antibiotic.
DISCUSSION
Here we report that epirubicin, and more generally the group of
anthracyclines, are very effective at conferring protection against
severe sepsis inmice, even when used up to 24 hr after the onset
of infection. This therapeutic window is likely to be sufficient to
make these drugs good candidates as useful therapeutic options
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Figure 6. Epirubicin Confers Protection against Severe Sepsis in a Therapeutic Manner
(A) Survival of C57BL/6 WT animals subjected to CLP treated with PBS or epirubicin (same dose as in Figure 1) at indicated times in the absence of meropenem;
(B) with administration of meropenem (40 mg/g body weight/day) starting at the time of the procedure or (C) with meropenem treatment starting 12 hr after CLP.
n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (log-rank [Mantel-Cox]).
Immunity
Anthracyclines Induce Tolerance to Sepsisin the clinic to reduce the mortality of sepsis in most patients that
are either in the hospital or seek medical attention within the first
few hours of symptoms initiation.
Although we began our investigation of the use of anthracy-
clines in sepsis by virtue of their effects in inhibiting inflammatory
cytokine expression in myeloid cells in vitro, our studies have
identified a mode of protection that seems to be much stronger
and perhaps completely independent of such effects, and rather
manifests at the level of DNA damage response and autophagy-
induced protection in the lung. Thus, our findings uncover an
unexpected role for these pathways in tissue (lung) tolerance
to the pathological consequences of infection. These findings
are especially relevant given that agents discovered in studies
over the last few years targeting various proinflammatory cyto-
kines have had limited success in humans. Our studies suggest
a critical role for protecting host tissues thereby conferring pro-
tection against sepsis. Recent studies have highlighted the role
of tissue tolerance to infection as an important aspect of host
pathology (Medzhitov et al., 2012).
Interestingly, the protective effect of epirubicin seems to act
irrespectively of the host pathogen burden, revealing that it
confers disease tolerance to polymicrobial infection (Larsen
et al., 2010; Ra˚berg et al., 2009; Schneider and Ayres, 2008).
This finding reveals that pharmacologic agents that provide
tissue damage control can limit disease severity irrespectively
of pathogen load and represent a promising therapeutic strategy
against sepsis. Moreover, based on our identification of ATM
as a major mediator of epirubicin effects, we propose that this
protein and other components of the DNA damage response
machinery constitute regulators of tolerance, without affecting
pathogen resistance mechanisms.
Recent reports make our findings counterintuitive because
doxorubicin and daunorubicin have been shown to induce acute
inflammation when injected in the abdomen, where they induce
cytokine secretion (Krysko et al., 2011; Sauter et al., 2011). How-
ever, the concentrations of anthracyclines utilized in these
studies were more than 10-fold higher than those used here.
By using lower concentrations, we might reduce the cytotoxicity
of these drugs and the resulting release of proinflammatory
DAMPs by dying cells and reveal the additional pharmacological
effects mediated by the surviving target cells. Interestingly, fluo-Iroquinolones that are bacterial type II topoisomerase inhibitors,
as opposed to anthracyclines, which are eukaryotic type II topo-
isomerase inhibitors, were reported to have immunomodulatory
effects (Dalhoff and Shalit, 2003) when used in supratherapeutic
concentrations. Fluoroquinolones have been shown to protect
against LPS model of septic shock (Khan et al., 2000). Although
the molecular mechanisms that explain these effects have not
been elucidated, it has been proposed that higher doses of
fluoroquinolones can inhibit mammalian topoisomerase type II
enzymes in addition to their bacterial targets (Dalhoff and Shalit,
2003), an effect that can be achieved with very low doses of
anthracyclines.
The induction of autophagy is a common response to many
forms of cellular stress, including DNA damage (Mizushima
and Komatsu, 2011). The rationale for testing the role of
autophagy was based on the knowledge that ATM is a negative
regulator of mTOR and that mTOR is a negative regulator of
autophagy (Alexander et al., 2010a; Alexander et al., 2010b).
We therefore reasoned that if epirubicin activates ATM (as we
have confirmed), then it is possible that it induces autophagy.
This line of investigation made sense because several reports
(Chien et al., 2011; Nakahira et al., 2011) have suggested a pro-
tective role for autophagy in sepsis. To probe the contribution of
autophagy for the protective phenotype conferred by epirubicin,
we have used two different genetic deletions in the autophagy
pathway (LC3b and ATG7), and in both cases the protection nor-
mally conferred by epirubicin is lost. This is considered one of the
best and most compelling ways to test the contribution of auto-
phagy and the direction of autophagic flow (Klionsky et al., 2012).
Chien et al. have previously found that autophagy is transiently
induced in the rat liver after CLP (Chien et al., 2011) and later
made similar observations in the rat kidney (Hsiao et al., 2012).
Chien et al. have speculated that the transient induction of auto-
phagy in these organs could be required for protection and its
decline at a later stage could contribute to the functional failure
in liver during polymicrobial sepsis. After we found autophagy
induction by epirubicin, we thought that one reason to explain
anthracycline protection against CLP could be the sustained
activation of autophagy in the liver and/or kidney preventing its
decline as observed by Chien et al. Instead, we found that
both in the liver and in the kidney, treatment with epirubicin didmmunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc. 881
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phagy in the lung, a response that was not present in mice sub-
jected to CLP in the absence of epirubicin treatment. We also
report that epirubicin is highly protective when delivered directly
to the lung and that overexpression of ATG7 specifically in the
lung improves survival to CLP. Together, these observations
strongly suggest that lung protection is critical and likely domi-
nant because it prevents failure of additional organs, which
makes our findings all the more relevant as the lung is the organ
that often shows the first signs of dysfunction in septic patients
and drives the failure of other target organs, particularly the
kidney and later the liver (Hotchkiss and Karl, 2003).
Nakahira et al. demonstrate that depletion of the autophagic
proteins LC3b and beclin 1 enhanced the activation of cas-
pase-1 and secretion of IL-1b and IL-18 (Nakahira et al., 2011).
Although we also observe inhibition of IL-1b secretion in vitro
and in vivo by treatment with epirubicin, this finding is not depen-
dent on the decreased activation of caspase-1 mediated by
autophagy because even low concentrations of epirubicin lead
to higher levels of active caspase-1 (A.C., data not shown), but
this event is overshadowed by a strong inhibition of IL-1b, as
well as most proinflammatory mediators that are NF-kB depen-
dent, at the transcriptional level. We have now identified the
mechanism: epirubicin targets the N-terminal region of p65,
inhibiting transcription by blocking the DNA-binding ability of
NF-kB (A.C., data not shown). The Nakahira et al. report also
suggested to us that severe sepsis could cause DNA lesions
capable of activating the inflammasome leading to chronic
inflammation and that the induction of autophagy could block
the inflammasome and prevent excessive inflammation. To
address this possibility, we have used comet assays to look at
different types of DNA damage in response to bacterial chal-
lenge in the presence and absence of epirubicin. We did find
that E. coli alone triggers a small but measurable increase of
DNA single-strand breaks (A.N.-C., data not shown). However,
the presence of epirubicin does not decrease; rather, it increases
DNA damage as compared to E. coli alone. Therefore, epirubicin
does not decrease the generation of DNA-damaged species that
can activate the inflammasome. We conclude that while the
Nakahira et al. work clearly shows that autophagic proteins
regulate NALP3-dependent inflammation by preserving mito-
chondrial integrity, the autophagy protection conferred by epiru-
bicin to CLP does not depend on themechanisms demonstrated
in the Nakahira et al. (2011) paper, specifically the negative
regulation of IL-1b secretion by autophagy.
Interestingly, the protective phenotype of epirubicin is strik-
ingly similar to that of RIPK3-deficient mice (Duprez et al.,
2011), suggesting that epirubicin-mediated, ATM-dependent
autophagy induction can possibly prevent TNF-driven necropto-
sis in such key organs in sepsis pathology as the lung. In fact,
there have been recent works that support the role of autophagy
in the inhibition of necroptosis (Bray et al., 2012; Degenhardt
et al., 2006; Lu and Walsh, 2012; Shen and Codogno, 2012),
which could be achieved by targeting key necroptosis-signaling
components (such as RIPK1 and RIPK3) for degradation. It is
also possible that autophagy protects against severe sepsis
because its activation increases the degradation of proinflam-
matory mediators with an important role in sepsis, like HMGB1
(Li et al., 2011). In addition, increased effective autophagy can882 Immunity 39, 874–884, November 14, 2013 ª2013 Elsevier Inc.be beneficial in sepsis as a result of its critical role in the removal
of damaged mitochondria in an ATM-dependent manner (Valen-
tin-Vega and Kastan, 2012). The molecular mechanisms at the
basis of epirubicin-induced protection in sepsis by autophagy
are certainly an interesting topic for future studies.
EXPERIMENTAL PROCEDURES
Animal Model and Anthracycline Treatment
Animal care and experimental procedures were conducted in accordance with
Portuguese andUS guidelines and regulations after approval by the respective
local committees (Instituto de Medicina Molecular and Instituto Gulbenkian de
Cieˆncia). All mice used were 8–12 weeks old. Mice were bred and maintained
under specific pathogen-free (SPF) conditions. C57BL/6 and C57BL/6 Atm/
mice were obtained from the Instituto Gulbenkian de Cieˆncia (a kind gift from
Dr. Vasco Barreto). C57BL/6 Nrf2/ mice were provided originally from the
RIKEN BioResource Center (Koyadai) and subsequently by the Instituto
Gulbenkian de Cieˆncia. LC3b/ (B6129PF2/J background) and NMRI mice
were purchased from Jackson and Charles River laboratories, respectively.
miR-146a-deficient mice were generated in the Baltimore’s laboratory (Boldin
et al., 2011). Fancd2/ mice were generated by the Grompe laboratory
(Houghtaling et al., 2003). Atg7loxP/loxP were generated by Masaaki Komatsu
and obtained from the Green laboratory. AtmloxP/loxP mice were generated
and obtained from the F.W. Alt’s laboratory. CLP was performed as described
previously (Rittirsch et al., 2009). The endotoxemia model was performed by
injecting i.p. a single dose of 50 mg/g body weight of LPS (from E. coli serotype
026:B6; Sigma-Aldrich). Pulmonary monostrain infections were carried out as
described previously (Weber et al., 2011), with intranasal injection of Klebsiella
pneumoniae (ATCC13803) at 8 3 107 colony-forming units (CFUs). Epirubicin
(Sigma-Aldrich), doxorubicin (Sigma-Aldrich), and daunorubicin (Sigma-
Aldrich) and meropenem (AstraZeneca) were dissolved in PBS, and etoposide
(Sigma-Aldrich) was dissolved in DMSO, aliquoted, and stored at –80C.
Epirubicin and daunorubicin (0.6 mg/g body weight), doxorubicin (0.5 mg/g
body weight), and etoposide (2 mg/g body weight) were injected i.p. at 0 and
24 hr following CLP. Meropenem (20 mg/g body weight b.i.d.) was injected
i.p. for 5 consecutive days.
Colony-Forming Units Assay
Blood samples from septic or mock CLPmice were collected by cardiac punc-
ture at indicated times after surgery. Mice were subsequentially perfused in
toto with 10 mL ice cold PBS and spleen, liver, and kidneys were surgically
removed and homogenized in 5 mL of sterile PBS. Serial dilutions of blood
and tissue homogenates were immediately plated on Trypticase Soy Agar II
plates supplemented with 5% Sheep Blood. CFUs were counted after a
12 hr incubation at 37C.
Serology and Cytokine Measurement
Plasma from blood samples obtained 24 hr post-CLP was collected after
centrifugation. LDH, CK, ALT, and urea levels were measured with the
BioAssay Systems kits (BioAssay Systems) according to company’s protocol.
Levels of TNF, IL-1b, and IL-6 were measured with the murine ELISA kits (R&D
Systems) according to company’s protocol. Levels of HMGB1 were assessed
with a murine ELISA kit (Shino Test Corporation) according to company’s
protocol.
Histology
Mice were euthanized and perfused in toto with 10 mL ice cold PBS, and lungs
and livers were surgically removed. Livers were placed in 10%phosphate buff-
ered formalin for 24 hr after which they were embedded in paraffin. Sections
were subsequently incubated with a primary antibody reactive to HMGB1
(Abcam) followed by incubation with biotinylated secondary antibody and
then with biotinylated horseradish peroxidase. Staining was developed by
addition of diaminobenzidine (DAB) substrate (Vector Labs) and counter-
stained with hematoxylin. Lungs were embedded in Tissue-Tek OCT (Sakura)
and snap frozen in liquid nitrogen. Lung sections (7 mm) were fixed in 1%
paraformaldehyde in PBS for 2 min, followed by methanol at 20C for
10 min and then in acetone for 2 min. Detection of LC3b and histone gH2AX
Immunity
Anthracyclines Induce Tolerance to Sepsiswas performed by incubating sections overnight at 4C with rabbit polyclonal
antibodies specific for, respectively, LC3b (L7543, Sigma Aldrich) and gH2AX
(phosphoS139) (ab2893; Abcam); incubation with a secondary DyLight 488-
coupled antibody (Jackson ImmunoResearch Laboratories) was for 1 hr at
room temperature. Sections were counterstained with DAPI (0.5 mg/mL) to
visualize DNA and mounted in Vectashield (Vector Laboratories) before
confocal microscopy. Samples were examined with a Zeiss LSM 510 META
laser scanning confocal microscope (Carl Zeiss). The acquired images were
analyzed with a MATLAB (Mathworks) routine developed in-house to perform
automatic threshold segmentation and enumeration of individual cell nuclei
stained with DAPI.
In Vivo Viral Infection and Viral Titer Assay
Murid herpesvirus-4 infection and viral particle quantification was performed
as previously described (Marques et al., 2008). Briefly, mice were intranasally
inoculated with 1,000 PFU of MuHV-4 strain 68 in 20 ml of PBS under light iso-
flurane anesthesia. At 6 and 12 days postinfection, lungs were removed and
homogenized in 5 mL of Glasgow’s modified Eagle’s medium (GMEM). Infec-
tious virus titers in freeze-thawed lung homogenates were determined by serial
diluted suspension assay with Baby hamster kidney cells (BHK-21) cultured in
GMEM supplemented with 10% fetal bovine serum, 10% tryptose phosphate
broth, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin
(GMEM). Plates were incubated for 4 days, fixed with 10% formal saline,
and counterstained with toluidine blue. Viral plaques were counted with a plate
microscope. Cre-adenovirus were obtained from the University of Iowa,
prepared as a calcium-phosphate coprecipitate, and incubated for 20 min at
room temperature. Atg7loxP/loxP and ATMloxP/loxP were subjected to light iso-
flurane anesthesia and allowed to inhale 125 mL of virus at a concentration
of 2.5 3 107 PFU. Additionally, WT C57BL/6 mice were included as controls.
Mice were allowed to rest for 5 days after inhalation, after which they were
subjected to CLP.
Stainings and Flow Cytometry
Peritoneal infiltrating leukocytes from either WT or LC3b-GFP transgenic ani-
mals were obtained 24 hr post CLP by lavage with 5mL of sterile ice-cold PBS,
washed, and blocked with mouse Ab anti-FcgIII/II (clone 93) receptor diluted in
PBS containing 2% FCS (v/v) for 20 min at 4C. Surface markers were
detected by incubating for 30 min at 4C with mouse Ab anti-CD4 (clone
GK1.5), anti-CD8 (clone 53-6.7), anti-CD19 (clone 6D5), anti-Ly-6G (clone
1A8) (all Biolegend), and anti-neutrophil monoclonal antibody (clone 7/4)
(Abcam). Dead cells were excluded by costaining with propidium iodide. Total
cell number was determined by flow cytometry with a fixed number of latex
beads (Beckman Coulter) coacquired with a pre-established volume of
the cellular suspension. For phospho-ATM intracellular staining, stimulated
THP-1 cells were washed and fixed with ice-cold methanol. Mouse Ab anti-
phospho-ATM pS1981, clone 10H11.E12 (IgG1k) was incubated for 60 min
at room temperature followed by an incubation of secondary Ab conjugated
with Alexa 488 (Molecular Probes). Fluorescence was measured by flow
cytometry and data analyzed with FlowJo software.
Immunoblotting
Mouse phospho-ATM (4526, Cell Signaling, 1:1,000 dilution), rabbit total ATM
(2873, Cell Signaling, 1:1000 dilution), rabbit LC3b (Sigma, 1:1000 dilution) and
the rabbit Fancd2 (Novus Biologicals; 1:1000 dilution) Ab were used overnight
at 4C. Primary Ab were detected with peroxidase conjugated secondary Ab
(1 hr; RT) and developed with SuperSignal chemiluminescent detection kit
(Pierce).
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